

Early Education Urged to Delay Sexual Risk Taking

BY DIANA MAHONEY
New England Bureau

Sexually risky behaviors on the part of adolescents is nothing new, but the age at which these behaviors begin is. In fact, new data suggest that sexual risk taking often begins in middle school.

Baseline data collected in spring 2005 from 4,457 middle school students aged 11-14 years at 14 urban schools participating in Project Connect, an 8-year multi-level intervention study, showed that more than 9% of the students surveyed reported ever having sexual intercourse, and 8% reported ever having oral sex.

In total, about 12% reported any sexual activity. Of those who reported having had intercourse, 36% were aged 11 years or younger at first sex, 27% were 12 years old, 28% were 13 years old, and 9% were aged 14 or older. In addition, of those who reported having had intercourse, 43% reported having had multiple sex partners.

Given their young age at sexual onset, "these youth are at very high risk for adverse health outcomes," Project Connect investigator Christine J. DeRosa, Ph.D., said at the annual meeting of the Society for Adolescent Medicine in Boston. As such, "behavioral and health education are imperative for all youth beginning early in middle school, and the involvement of parents, health care providers, and community leaders is also critical."

Generic Version Of Venlafaxine FDA Approved

The first generic formulation of the antidepressant venlafaxine has been approved by the Food and Drug Administration.

The FDA announced in early August that it had approved the generic version of the immediate-release formulation of Effexor in 25-mg, 37.5-mg, 50-mg, 75-mg, and 100-mg tablets, the same doses available for Effexor. The generic manufacturer, Teva Pharmaceuticals USA, announced that shipment of the tablets would start immediately.

Teva has exclusive rights to market the generic formulation for 180 days after approval, after which time the FDA can approve applications for other generic formulations of venlafaxine, a serotonin norepinephrine reuptake inhibitor (SNRI).

Effexor, marketed by Wyeth Pharmaceuticals Inc., was approved for major depressive disorder in 1993; the extended-release formulation (Effexor XR) was approved in 1997.

Other recently approved first-time generic drugs include escitalopram tablets, the generic version of the selective serotonin reuptake inhibitor (SSRI) Lexapro, and sertraline in tablet and oral concentrate formulations, the generic version of the SSRI Zoloft.

—Elizabeth Mechtie

The goal of such interventions should be to assist those youth who have already engaged in some sexual activity to return to abstinence, said Dr. DeRosa of Health Research Association Inc., a University of Southern California affiliate that is facilitating the Centers for Disease Control-sponsored project. "For the majority of youth who have not engaged in sexual activities, the goal should be to further delay the onset of sexual initiation."

How the interventions should look and

be implemented is a matter of much debate. Should they focus on abstinence or contraception? Should they be school or clinic based? Should they be voluntary or mandatory? The "best" intervention is one that identifies and targets the range of risk and protective factors that influence initiation of sex, number of partners, condom use, and contraception use, and this will vary depending on the individuals or populations being served, according to Douglas Kirby, Ph.D., a senior research scientist with

ETR Associates in Scotts Valley, Calif.

In a 2001 report for the National Campaign to Prevent Teen Pregnancy called "Emerging Answers: Research Findings on Programs to Reduce Teen Pregnancy" (www.teenpregnancy.org/resources/data/pdf/emersum.pdf), Dr. Kirby reviewed the results of 300 studies on risk and protective factors across multiple domains, from which emerged a complex picture of the antecedents of adolescent sexual risk taking.

FIRST
IN A NOVEL
CLASS OF
SLEEP
AGENTS

Rozerem is indicated for the treatment of insomnia characterized by difficulty with sleep onset. Rozerem can be prescribed for long-term use. Rozerem should not be used in patients with hypersensitivity to any components of the formulation, severe hepatic impairment, or in combination with fluvoxamine. Failure of insomnia to remit after a reasonable period of time should be medically evaluated, as this may be the result of an unrecognized underlying medical disorder. Hypnotics should be administered with caution to patients exhibiting signs and symptoms of depression. Rozerem has not been studied in patients with severe sleep apnea, severe COPD, or in children or adolescents. The effects in these populations are unknown. Avoid taking Rozerem with alcohol. Rozerem has been associated with decreased testosterone levels and increased prolactin levels. Health professionals should be mindful of any unexplained symptoms possibly associated with such changes in these hormone levels. Rozerem should not be taken with or immediately after a high-fat meal. Rozerem should be taken within 30 minutes before going to bed and activities confined to preparing for bed. The most common adverse events seen with Rozerem that had at least a 2% incidence difference from placebo were somnolence, dizziness, and fatigue.

Please see adjacent Brief Summary of Prescribing Information.